The biotechnology sector has fascinated me for a long time, and my experience working in "big pharma" only increased my interest. My goals with my research are simple - first and foremost, I strive to identify undervalued stocks that have future catalysts that can greatly push the price per share up. Another area that I focus on is combatting the "naysayers" - those individuals who either due to a lack of due diligence or who have ulterior motives - who spread news, gossip, and other misinformation. Most retail investors do not have an opportunity to conduct hours of research a day to sort through the vast array of information, and thus can be easily influenced by positive or negative information that may not be entirely accurate. In terms of my Seeking Alpha article writing, it is my hope to identify potential opportunities that may be overlooked, pitfalls that may be avoided, and to also generate discussion about potential deals or binary events that could impact investors in the biotech sector.
I trend towards contrarian and hope to scoop up extreme values. As the winds deep inside the maple forest pass over me, I hope to be imbibed with investment knowledge. May the energy in each of the leaves and flowers of the forest guide me towards extreme profits...
Currently Vice President of Business Development dedicated to the discovery and creation of shareholder value for Life Science companies.
--Extensive Scientific Research experience in Pharmaceutical and Medical Device Companies AMGEN, ALLERGAN
--Experience as Technical Liaison/Advisor for prominent financial institutions focused on Healthcare and Biotech investments
Prior experience includes:
AMGEN: (Research Scientist ) Drug Product Process Development, Drug Engineering, FDA technology- liaison, Product Characterization, Commercial Manufacturing Support, Commercial Drug Development , Drug Formulation and Pre-commercial Drug Product Tech Transfer.
ALLERGAN: (Research Scientist) Project design and management of proprietary materials and data for medical device and medical aesthetic products. Scientific research team lead of collagen and capsular-contracture studies for devices. Biomaterial optimization applying advanced histology, cell culture and immunohistochemistry.
OPUS Point Partners/OPN Capital Markets/ National Securities: Scientific Advisor and technology liaison. Worked alongside lead market strategist and lead biotech analyst at National Securities for The Biotech Group. Lead the due diligence process for the Managing Director at OPN Capital Markets, reviewing product mechanisms,intellectual property and overall technology/concept viability.
Mr. Williams is a strategic advisor to automotive companies focused on PHEV drive trains, alternative energy grid storage and new battery technologies. He assists automotive companies commercializing highly efficient, environmentally friendly, powertrain technologies for light, medium, and heavy duty trucks, buses, vans and SUVs.
Background in engineering, which after years quite honestly bored me. I consider myself a serial entrepreneur and avid day trader. Particularly interested in small biopharmaceutical & biotech. I travel extensively, and I do mean extensively and love every minute of it. Currently living between Singapore and Knoxville, TN.
Waiting for PVCT to get to $100 so I can retire. Doesn't seem like that will be too far away now!
Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion.
I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).
I am an individual investor. My education is in Elementary Education and I am retired. I ran my own small business for 18 years. My main stock interest is in biotech. I have owned many different biotechs for 28 years. About 10 have been bought out.